Recruitment specialist Trialbee unveils new patient recruitment and clinical trial platform

Patients in a hospital waiting room
Recruitment specialist Trialbee released a new digital patient engagement solution designed to help increase patient retention, protocol compliance and treatment adherence by using customized messaging and support. (Getty/SuwanPhoto)

Recruitment specialist Trialbee released a new digital patient engagement solution designed to help increase patient retention, protocol compliance and treatment adherence by using customized messaging and support.

The platform gives sponsors, CROs and test sites improved protocol adherence and reduced data variability. It was developed to reduce drop-outs and improve patient retention for more complete sets of data points and higher-quality data.

“Keeping study patients enrolled and actively engaged in a trial impacts data quality and boosts the statistical power of a study—enabling improved ability to detect differences between treatment groups and speed the process to market,” Hanne Van de Beek, the company’s customer project manager, said in a statement.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

The platform’s app is iOS- and Android-compatible, and include patient-friendly features that can be customized, giving patients the tools and information they need to foster engagement throughout the trial, the company said.

Suggested Articles

Nearly 200 companies have stopped or delayed their trials over the pandemic, with phase 2 tests the most affected.

LabCorp’s CRO unit Covance has updated its Xcellerate platform to seek out as well as help restore and continue ongoing trials hit by the pandemic.

Contract research organization PPD has boosted its COVID-19 research by adding five new molecular, serology and functional assays.